Female Infertility and IVF: Causes, Evaluation, and Treatment Planning
Key Takeaways
Female infertility is not one disease. It is a cluster of problems that can involve ovulation, the fallopian tubes, the uterus, ovarian reserve, or implantation. IVF can bypass some barriers — especially damaged tubes — but the better first move is still finding the main obstacle.
Key evidence: ASRM: Fertility evaluation of infertile women (2021) WHO infertility fact sheet (2020) PCOS and infertility overview (Collée et al., 2021)
Contents
- What is female infertility?
- Main causes
- How evaluation usually works
- When IVF becomes a fit
- Practical notes for international patients
- Clinical note
- Questions worth asking before deciding
- FAQ
- Sources
Delayed conception rarely has a single label. Ovulation, tubes, uterus, age-related egg quality, endometriosis — or more than one of these — can sit behind the same waiting room story. IVF matters in that picture. It is not, by default, the first page of the plan. The useful sequence is still diagnosis first, then a treatment that matches the actual barrier.
What is female infertility?
Short answer: Female infertility usually means no pregnancy after 12 months of regular unprotected intercourse — or after about 6 months when age is 35 or older — and it covers a range of problems affecting ovulation, tubes, uterus, ovarian reserve, or implantation.
ASRM and WHO treat infertility as a disease of the reproductive system. Naming the cause early helps avoid both delay and unnecessary treatment (PMID: 34607703; PMID: 33575673). Shared international terms for infertility and fertility care are set out in the ICMART/WHO glossary (PMID: 28760517).
Main causes
Short answer: Most cases fall into five overlapping groups: ovulation disorders, tubal factor, uterine or cervical factors, endometriosis, and age-related decline in ovarian reserve.
Ovulation disorders
These account for roughly a quarter to a third of female infertility. Common patterns include PCOS, hypothalamic suppression (stress, underweight, extreme exercise), thyroid or prolactin disorders, and premature ovarian insufficiency. Many respond first to ovulation induction — for example letrozole, clomiphene, or gonadotrophins — before IVF enters the conversation (PMID: 34338572).
Tubal factor
Blocked or damaged tubes can stop egg pickup, fertilization, or embryo transport. Pelvic infection, prior surgery, and endometriosis are frequent backgrounds. This is where IVF often earns its place: it simply bypasses the tube when repair is unlikely to help (PMID: 34607703).
Uterine and cervical factors
Cavity-distorting fibroids, polyps, intrauterine adhesions, congenital anomalies, and selected cervical problems can hinder implantation or raise miscarriage risk. Some of these are better corrected surgically before an embryo transfer.
Endometriosis
Endometriosis can distort pelvic anatomy, sustain inflammation, and in some cases affect egg or implantation biology. Surgery, IVF, or a sequenced plan may all be reasonable — the choice depends on stage, symptoms, age, and prior attempts.
Age and ovarian reserve
Age remains the strongest independent fertility variable. Egg number falls (AMH, antral follicle count). Egg quality falls with it, so chromosomally abnormal embryos become more common. IVF can improve cycle efficiency. It does not rewind ovarian ageing.
How evaluation usually works
Short answer: A standard workup builds from history and cycle pattern, then adds targeted tests: early-cycle hormones, pelvic ultrasound, ovarian reserve markers, tubal assessment (HSG or similar), and cavity review when needed.
| Test | What it clarifies | Typical timing |
|---|---|---|
| History and cycle review | Ovulation pattern, risk factors, prior surgery | First visit |
| Day 2–3 hormones (FSH, LH, E2, TSH, prolactin, AMH) | Reserve and endocrine context | Days 2–5 |
| Pelvic ultrasound | Anatomy, cysts, lining, antral follicles | Often early follicular phase |
| Tubal test (HSG, HyCoSy, or selected laparoscopy) | Patency and cavity outline | After menses, before ovulation |
| Cavity assessment (saline scan, hysteroscopy) | Polyps, adhesions, distorting fibroids | When clinically indicated or before IVF |
| Laparoscopy | Endometriosis, adhesions, subtle tubal disease | Not routine screening for every patient |
Laparoscopy is reserved for strong suspicion of endometriosis, dense adhesions, or a surgical question that imaging cannot settle (PMID: 34607703; PMID: 32603474).
When IVF becomes a fit
Short answer: IVF is usually discussed when both tubes are badly damaged, simpler care has failed, reserve is declining and time is short, a significant male factor needs ICSI, or natural conception is otherwise unlikely.
Common transition points include:
- Severe bilateral tubal disease or large communicating hydrosalpinx.
- Several failed ovulation-induction or IUI cycles.
- Low reserve where waiting itself is the risk.
- Moderate-to-severe male factor needing ICSI.
- Advanced endometriosis after simpler options have been exhausted.
- Unexplained infertility after a complete workup.
- Situations where preimplantation genetic testing is clinically indicated.
IVF adds control over fertilization timing, embryo selection, and transfer timing. Results still hinge on age, embryo quality, the uterine environment, and the underlying diagnosis.
Practical notes for international patients
Short answer: Basic evaluation can often be completed in one or two visits over a week. An antagonist IVF cycle typically needs about 10–14 days on site; a frozen transfer can be a shorter return trip later.
Bring prior hormone results, ultrasounds, HSG films, operative notes, and any genetic reports. Missing paperwork is the most common reason a plan loses a full cycle.
Clinical Note
Dr. Senai Aksoy: Three decision points come up constantly in this workup — pure anovulatory PCOS, “possible hydrosalpinx” on a paper report, and the unexplained label.
When anovulation is the only barrier. If the tubes are open, semen is normal, and the main problem is that eggs are not being released, the first job is controlled ovulation — not IVF. Letrozole is usually first line. When ovulation is documented and timed intercourse is possible, I do not add IUI automatically in the first cycle just because the diagnosis is PCOS; with normal sperm the incremental gain from IUI can be limited. Under 35, three to six ovulatory letrozole cycles are often reasonable, with a full re-check after three if there is no pregnancy. Between 35 and 37 I usually reassess after about three well-run cycles. From 38 onward — especially with long infertility or falling reserve — IVF enters the conversation earlier, but age 38 alone does not send every untreated patient straight to IVF. AMH is not an IVF indication by itself: it mainly predicts egg yield in stimulation. In PCOS it is often high, and high does not mean high egg quality. What pushes me toward earlier IVF is the combination of age ≥38, age-discordant low AMH and AFC, long infertility, enough failed ovulatory cycles, an added male or tubal factor, or a wish for more than one child with little calendar left. As I tell patients: “AMH alone is not an IVF indication. But when it shows, together with your age, that time is narrowing and simpler treatments are losing ground, we do not repeat the same method for months.” The 2023 international PCOS guideline likewise keeps letrozole first line in anovulatory PCOS without other infertility factors, and places IVF after first- and second-line ovulation treatment has failed (PMID: 37580314).
When the HSG only says “possible hydrosalpinx.” A written phrase is not an operation order. Before irreversible salpingectomy or proximal occlusion I want confirmation that a communicating hydrosalpinx is real — recurrent ultrasound fluid, a dilated distal tube on HSG that fills from the cavity, fluid reappearing in the endometrium, or laparoscopy. Unilateral disease is not automatically safe: fluid can still reach the cavity and blunt IVF. If I only have a report without films, if spasm or pooling could explain the image, if ultrasound is clean and the HSG is borderline, or if “blocked tube” was written without describing a true hydrosalpinx, I verify first. For international patients the sequence is: DICOM or full HSG series, not the text alone; prior ultrasound and infection history; expert TVUS in Istanbul; repeat HSG or HyCoSy if doubt remains; operate only after confirmation. When surgery is needed and anatomy allows, I prefer salpingectomy; when the tube is densely stuck to the ovary or low reserve makes ovarian blood supply a concern, proximal occlusion can be the ovary-sparing choice. The aim is not “remove a tube at all costs” — it is to stop hydrosalpinx fluid reaching the cavity while protecting the ovary. WHO guidance for confirmed hydrosalpinx before IVF likewise supports salpingectomy or tubal occlusion, with method choice guided by adhesions and surgical feasibility (WHO 2025 infertility guideline).
When the label is “unexplained.” I first check that ovulation, reserve, cavity, at least one open tube, and adequate semen assessment were truly completed. Unexplained means today’s standard tests have not shown a cause — not that nothing is wrong. Under 35 with short duration and good reserve, a brief expectant window can be reasonable; when treating, I usually try three to four cycles of oral stimulation with IUI, then move to IVF rather than stacking many gonadotrophin–IUI cycles (PMID: 32106976). Between 35 and 37 I rarely extend beyond two to three well-planned IUI cycles. From 38, especially with long infertility or falling reserve, early IVF is often the more rational use of calendar time. The two misconceptions I hear most: “all tests normal, so our chance must be normal,” and “unexplained means we need a long list of advanced immune or implantation tests.” Standard tests do not fully measure egg quality, tubal pickup, gamete interaction, or embryo chromosomes — but missing a label also does not obligate every experimental panel. Sometimes the better step is the age-appropriate treatment rung, not another test.
Closing line I use: “Simpler treatments are valuable when they are used in the right patient for the right duration. Sending a young woman with pure anovulation to early IVF is as wrong as leaving a woman over 38 — or with falling reserve — in months of low-probability cycles.”
Questions worth asking before deciding
Short answer: Use these as a neutral checklist with your clinician — not as a sales script.
- What is the main barrier in my case: ovulation, tubes, uterus, endometriosis, reserve, male factor, or still unexplained?
- Is there a simpler step worth trying first, and what is its realistic chance at my age?
- What live-birth expectation fits this diagnosis and age band — per cycle and over two to three cycles?
- Do I need PGT-A, and what does it add in time and complexity?
- How many days on site are realistically required from stimulation start to pregnancy test?
- Which modifiable factors (weight, smoking, thyroid, prolactin, vitamin D) should be addressed before starting?
Related reading in English:
- Unexplained infertility: what the label means
- Endometriosis and infertility
- Hydrosalpinx and infertility
FAQ
Does female infertility always mean IVF is needed?
No. Ovulation problems, selected uterine findings, and some milder patterns may respond to medication, surgery, or IUI before IVF is proportionate.
When does IVF help most?
Most clearly with severe tubal disease, when age or reserve makes delay costly, after several lower-intensity failures, or when a meaningful male factor needs ICSI in the same pathway.
Why keep investigating if IVF is available?
Because IVF does not erase every obstacle. An untreated hydrosalpinx communicating with the cavity, an unrepaired cavity problem, or an active endocrine disorder can still blunt outcomes. ASRM guidance notes that implantation and live-birth rates may be roughly halved when hydrosalpinx is left untreated before IVF (PMID: 33642065).
Should evaluation start before 12 months?
Yes, often after about six months from age 35, or sooner with irregular cycles, known endometriosis, prior pelvic infection or surgery, or a known male factor (PMID: 34607703).
Is ovarian reserve testing enough to decide the plan?
No. AMH and follicle count estimate reserve and likely stimulation response. They do not replace tubal, uterine, ovulation, and semen assessment. The plan follows the whole picture, not one number.
Sources
- Practice Committee of the American Society for Reproductive Medicine. “Fertility evaluation of infertile women: a committee opinion.” Fertil Steril. 2021. PMID: 34607703
- World Health Organization. “Infertility fact sheet.” 2020. PMID: 33575673
- Collée J et al. “Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments.” Gynecol Endocrinol. 2021. PMID: 34338572
- Howell EP et al. “Preconception Evaluation Before In Vitro Fertilization.” Obstet Gynecol Surv. 2020. PMID: 32603474
- Zegers-Hochschild F et al. “The International Glossary on Infertility and Fertility Care, 2017.” Fertil Steril. 2017. PMID: 28760517
- Practice Committee of the American Society for Reproductive Medicine. “Role of tubal surgery in the era of assisted reproductive technology: a committee opinion.” Fertil Steril. 2021. PMID: 33642065
- Teede HJ et al. “Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.” J Clin Endocrinol Metab. 2023. PMID: 37580314
- Practice Committee of the American Society for Reproductive Medicine. “Evidence-based treatments for couples with unexplained infertility: a guideline.” Fertil Steril. 2020. PMID: 32106976
- World Health Organization. “WHO guideline for the prevention, diagnosis and treatment of infertility” (hydrosalpinx before IVF). 2025. NCBI Bookshelf
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.